SCHEMBL9923913

SCHEMBL9923913

Cc1ccc2nc(NC(=O)OC(C)(C)C)c(Cl)n2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.43
HPGD P15428 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 2/20 0.43
TSHR P16473 1/20 0.43
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ABL1 P00519 4/20 0.39
LRRK2 Q5S007 2/20 0.39
LMNA P02545 2/20 0.38
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38
LCK P06239 3/20 0.38
GABRB1 P18505 2/20 0.38
ATR Q13535 1/20 0.38
GABRD O14764 1/20 0.38
GABRA4 P48169 1/20 0.38
MAP3K5 Q99683 1/20 0.37
ALB P02768 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923990 0.87 KDM4E (0.44) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL15631825 0.84 TRPA1 (0.42) KDM4EHPGDALDH1A1SMN1; SMN2ABL1
SCHEMBL9924006 0.81 ALDH1A1 (0.43) KDM4EHPGDALDH1A1HSD17B10RAB9A
SCHEMBL22519306 0.80 KDM4E (0.41) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL9924039 0.80 ALDH1A1 (0.44) KDM4EHPGDALDH1A1SMN1; SMN2ABL1
SCHEMBL15631803 0.75 CYP11B1 (0.44) KDM4EALDH1A1RAB9ASMN1; SMN2ABL1
SCHEMBL9942081 0.73 MCHR1 (0.41) ABL1LRRK2LMNAPOLBGABRB1
SCHEMBL22519299 0.72 ALDH1A1 (0.40) KDM4EHPGDALDH1A1ABL1LMNA
SCHEMBL9923873 0.72 ALDH1A1 (0.48) KDM4EHPGDALDH1A1HSD17B10RAB9A
SCHEMBL9924052 0.71 KDM4E (0.45) KDM4EHPGDALDH1A1HSD17B10RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 KDM4E 3480/4885HPGD 2697/4885ALDH1A1 2230/4885
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 KDM4E 3480/4885HPGD 2697/4885ALDH1A1 2230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.